HomeCompareASLN vs EQR

ASLN vs EQR: Dividend Comparison 2026

ASLN yields 333.33% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASLN wins by $3112.20M in total portfolio value
10 years
ASLN
ASLN
● Live price
333.33%
Share price
$0.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3112.25M
Annual income
$1,957,209,378.70
Full ASLN calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — ASLN vs EQR

📍 ASLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASLNEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASLN + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASLN pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASLN
Annual income on $10K today (after 15% tax)
$28,333.33/yr
After 10yr DRIP, annual income (after tax)
$1,663,627,971.90/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, ASLN beats the other by $1,663,623,317.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASLN + EQR for your $10,000?

ASLN: 50%EQR: 50%
100% EQR50/50100% ASLN
Portfolio after 10yr
$1556.15M
Annual income
$978,607,427.15/yr
Blended yield
62.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ASLN
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASLN buys
0
EQR buys
0
No recent congressional trades found for ASLN or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASLNEQR
Forward yield333.33%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$3112.25M$47.8K
Annual income after 10y$1,957,209,378.70$5,475.61
Total dividends collected$3000.20M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: ASLN vs EQR ($10,000, DRIP)

YearASLN PortfolioASLN Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$44,033$33,333.33$11,380$679.82+$32.7KASLN
2$184,291$137,175.49$13,014$837.25+$171.3KASLN
3$733,748$536,556.79$14,961$1,036.20+$718.8KASLN
4$2,781,635$1,996,524.01$17,297$1,289.22+$2.76MASLN
5$10,050,002$7,073,652.70$20,121$1,613.15+$10.03MASLN
6$34,638,543$23,885,041.43$23,561$2,030.84+$34.61MASLN
7$114,000,322$76,937,080.16$27,783$2,573.54+$113.97MASLN
8$358,625,914$236,645,569.53$33,013$3,284.39+$358.59MASLN
9$1,079,474,884$695,745,156.26$39,547$4,223.51+$1079.44MASLN
10$3,112,247,504$1,957,209,378.70$47,791$5,475.61+$3112.20MASLN

ASLN vs EQR: Complete Analysis 2026

ASLNStock

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Full ASLN Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ASLN vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASLN vs SCHDASLN vs JEPIASLN vs OASLN vs KOASLN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.